Sentinel lymph node detection in thyroid carcinoma using 
            68Ga-tilmanocept PET/CT: a proof-of-concept study protocol

Lisa H de Vries; Lutske Lodewijk; Bart de Keizer; Inne Hm Borel Rinkes; Menno R Vriens

doi:10.2217/fon-2022-0165

Sentinel lymph node detection in thyroid carcinoma using ⁶⁸Ga-tilmanocept PET/CT: a proof-of-concept study protocol

Lisa H de Vries, Lutske Lodewijk, Bart de Keizer, Inne Hm Borel Rinkes, Menno R Vriens^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

11 Downloads (Pure)

Abstract

Sentinel lymph node biopsy (SLNB) is a diagnostic staging procedure. The procedure aims to identify the first draining lymph node(s), which are most likely to contain metastases. SLNB is applied in various cancers, but not currently in thyroid carcinoma. However, treatment strategies are changing, making SLNB clinically relevant. SLNB may lead to more accurate staging, prevent unnecessary treatment and help achieve earlier curation. 68Ga-tilmanocept PET/computed tomography (CT) can better localize sentinel lymph nodes (SLNs) near the primary tumor than planar scintigraphy and single-photon emission computed tomography (SPECT)/CT. This paper describes the rationale and design of a study investigating SLNB using 68Ga-tilmanocept PET/CT and indocyanine-green- 99mTc-nanocolloid in ten differentiated and medullary thyroid carcinoma patients. Localization and number of SLNs, pathology result, optimal scan protocol, surgical time and surgeon's experience are examined. Clinical Trial Registration: 2021-002470-42 (EudraCT).

Original language	English
Pages (from-to)	3493-3499
Number of pages	7
Journal	Future Oncology
Volume	18
Issue number	31
Early online date	7 Sept 2022
DOIs	https://doi.org/10.2217/fon-2022-0165
Publication status	Published - 1 Oct 2022

Keywords

Ga-tilmanocept PET/CT
ICG- Tc-nanocolloid
sentinel lymph node
thyroid carcinoma

Access to Document

10.2217/fon-2022-0165Licence: CC BY

fon-2022-0165Final published version, 1.32 MBLicence: CC BY

Cite this

@article{f00bac134cc84baf91f2ffd90e872cfd,

title = "Sentinel lymph node detection in thyroid carcinoma using 68Ga-tilmanocept PET/CT: a proof-of-concept study protocol",

abstract = "Sentinel lymph node biopsy (SLNB) is a diagnostic staging procedure. The procedure aims to identify the first draining lymph node(s), which are most likely to contain metastases. SLNB is applied in various cancers, but not currently in thyroid carcinoma. However, treatment strategies are changing, making SLNB clinically relevant. SLNB may lead to more accurate staging, prevent unnecessary treatment and help achieve earlier curation. 68Ga-tilmanocept PET/computed tomography (CT) can better localize sentinel lymph nodes (SLNs) near the primary tumor than planar scintigraphy and single-photon emission computed tomography (SPECT)/CT. This paper describes the rationale and design of a study investigating SLNB using 68Ga-tilmanocept PET/CT and indocyanine-green- 99mTc-nanocolloid in ten differentiated and medullary thyroid carcinoma patients. Localization and number of SLNs, pathology result, optimal scan protocol, surgical time and surgeon's experience are examined. Clinical Trial Registration: 2021-002470-42 (EudraCT). ",

keywords = "Ga-tilmanocept PET/CT, ICG- Tc-nanocolloid, sentinel lymph node, thyroid carcinoma",

author = "{de Vries}, {Lisa H} and Lutske Lodewijk and {de Keizer}, Bart and {Borel Rinkes}, {Inne Hm} and Vriens, {Menno R}",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors.",

year = "2022",

month = oct,

day = "1",

doi = "10.2217/fon-2022-0165",

language = "English",

volume = "18",

pages = "3493--3499",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "31",

}

TY - JOUR

T1 - Sentinel lymph node detection in thyroid carcinoma using 68Ga-tilmanocept PET/CT

T2 - a proof-of-concept study protocol

AU - de Vries, Lisa H

AU - Lodewijk, Lutske

AU - de Keizer, Bart

AU - Borel Rinkes, Inne Hm

AU - Vriens, Menno R

PY - 2022/10/1

Y1 - 2022/10/1

N2 - Sentinel lymph node biopsy (SLNB) is a diagnostic staging procedure. The procedure aims to identify the first draining lymph node(s), which are most likely to contain metastases. SLNB is applied in various cancers, but not currently in thyroid carcinoma. However, treatment strategies are changing, making SLNB clinically relevant. SLNB may lead to more accurate staging, prevent unnecessary treatment and help achieve earlier curation. 68Ga-tilmanocept PET/computed tomography (CT) can better localize sentinel lymph nodes (SLNs) near the primary tumor than planar scintigraphy and single-photon emission computed tomography (SPECT)/CT. This paper describes the rationale and design of a study investigating SLNB using 68Ga-tilmanocept PET/CT and indocyanine-green- 99mTc-nanocolloid in ten differentiated and medullary thyroid carcinoma patients. Localization and number of SLNs, pathology result, optimal scan protocol, surgical time and surgeon's experience are examined. Clinical Trial Registration: 2021-002470-42 (EudraCT).

AB - Sentinel lymph node biopsy (SLNB) is a diagnostic staging procedure. The procedure aims to identify the first draining lymph node(s), which are most likely to contain metastases. SLNB is applied in various cancers, but not currently in thyroid carcinoma. However, treatment strategies are changing, making SLNB clinically relevant. SLNB may lead to more accurate staging, prevent unnecessary treatment and help achieve earlier curation. 68Ga-tilmanocept PET/computed tomography (CT) can better localize sentinel lymph nodes (SLNs) near the primary tumor than planar scintigraphy and single-photon emission computed tomography (SPECT)/CT. This paper describes the rationale and design of a study investigating SLNB using 68Ga-tilmanocept PET/CT and indocyanine-green- 99mTc-nanocolloid in ten differentiated and medullary thyroid carcinoma patients. Localization and number of SLNs, pathology result, optimal scan protocol, surgical time and surgeon's experience are examined. Clinical Trial Registration: 2021-002470-42 (EudraCT).

KW - Ga-tilmanocept PET/CT

KW - ICG- Tc-nanocolloid

KW - sentinel lymph node

KW - thyroid carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85144584500&partnerID=8YFLogxK

U2 - 10.2217/fon-2022-0165

DO - 10.2217/fon-2022-0165

M3 - Review article

C2 - 36069284

SN - 1479-6694

VL - 18

SP - 3493

EP - 3499

JO - Future Oncology

JF - Future Oncology

IS - 31

ER -

Sentinel lymph node detection in thyroid carcinoma using ⁶⁸Ga-tilmanocept PET/CT: a proof-of-concept study protocol

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this